Paralysed Zenotech awaits Daiichi Sankyo booster dose
This article was originally published in Scrip
About five years since the Indian firm, Zenotech Laboratories, changed hands to Ranbaxy Laboratories and then indirectly to Daiichi Sankyo as a result of Ranbaxy's acquisition by the Japanese giant, intra-management disagreements appear to have near paralysed activity at the once promising biotech firm.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.